SummitTX Capital L.P. Buys Shares of 20,244 Vera Therapeutics, Inc. $VERA

SummitTX Capital L.P. bought a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,244 shares of the company’s stock, valued at approximately $814,000.

Other large investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Vera Therapeutics by 7.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after buying an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Vera Therapeutics by 22.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after buying an additional 17,907 shares during the last quarter. Jane Street Group LLC raised its position in Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after buying an additional 62,678 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Vera Therapeutics by 550.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after acquiring an additional 262,805 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of Vera Therapeutics by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after acquiring an additional 825 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on VERA. Wedbush boosted their price target on shares of Vera Therapeutics from $35.00 to $43.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Evercore set a $91.00 price objective on shares of Vera Therapeutics in a research report on Friday, May 15th. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Needham & Company LLC set a $125.00 target price on Vera Therapeutics in a research report on Wednesday, July 8th. Finally, Bank of America increased their target price on Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $84.58.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares in the company, valued at $6,429,346.20. This represents a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 83,250 shares of company stock worth $3,337,770. 15.90% of the stock is owned by insiders.

Vera Therapeutics Stock Up 1.7%

VERA stock opened at $33.05 on Friday. The company has a market cap of $2.37 billion, a P/E ratio of -5.97 and a beta of 0.92. Vera Therapeutics, Inc. has a 52 week low of $19.07 and a 52 week high of $56.05. The company’s 50-day moving average price is $36.95 and its 200 day moving average price is $39.68. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the prior year, the firm earned ($0.81) EPS. On average, research analysts expect that Vera Therapeutics, Inc. will post -6.37 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.